Antivirale ad uso diretto ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
107Juvenile idiopathic arthritis1

107. Juvenile idiopathic arthritis


Clinical trials : 447 Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-001577-24-IT
(EUCTR)
16/09/2021A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS)A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous - NI-0501-14 Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD).MAS in the context of pediatric and adult Systemic lupus erythematous (SLE).
MedDRA version: 21.1;Level: PT;Classification code 10071583;Term: Haemophagocytic lymphohistiocytosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Emapalumab
Product Code: [NI-0501]
INN or Proposed INN: Emapalumab
Product Name: Emapalumab
Product Code: [NI-0501]
INN or Proposed INN: Emapalumab
Product Name: Profilassi per Herpes Zoster
Product Code: [Profilassi per Herpes Zoster]
INN or Proposed INN: Antivirale ad uso diretto
Swedish Orphan Biovitrum AGNULLNAFemale: yes
Male: yes
41Phase 2;Phase 3United States;Czechia;Spain;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;Germany;Netherlands;China;Japan;Sweden